Currently out of the existing stock ratings of Alex Thompson, 45 are a BUY (72.58%), 17 are a HOLD (27.42%).

Alex Thompson

Work Performance Price Targets & Ratings Chart

Analyst Alex Thompson, currently employed at STIFEL, carries an average stock price target met ratio of 54.09% that have a potential upside of 54.1% achieved within 166 days.

Alex Thompson’s has documented 124 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ANAB, AnaptysBio at 29-Oct-2025.

Wall Street Analyst Alex Thompson

Analyst best performing recommendations are on DICE (DICE MOLECULES HOLDINGS LLC).
The best stock recommendation documented was for DICE (DICE MOLECULES HOLDINGS LLC) at 9/6/2022. The price target of $37 was fulfilled within 35 days with a profit of $18.05 (95.25%) receiving and performance score of 27.21.

Average potential price target upside

of $97.37 (22.2%) on ARGX (ARGENX NV ADR).
of $71.63 (53.48%) on ASND (ASCENDIS PHARMA AS).
of $11.62 (40.29%) on MORF (MORPHIC).

DICE Dice Molecules Holdings LLC VTYX Ventyx Biosciences ARGX argenx NV ADR ACRS Aclaris Therapeutics MORF Morphic PLRX Pliant Therapeutics TVTX Travere Therapeutics KDNY Chinook Therapeutics IMVT Immunovant MLTX MoonLake Immunotherapeutics VRDN Viridian Therapeutics AGLE Aeglea Bio Therapeutics ASND Ascendis Pharma AS APGE Apogee Therapeutics, Common Stock SYRE Spyre Therapeutics ANAB AnaptysBio

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score